Skip to main content
. 2012 Dec;86(24):13384–13396. doi: 10.1128/JVI.07234-11

TABLE 1.

Sensitivities of multidrug-resistant clinical isolates to various PIsa

Virus IC50, mean ± SD (μM) (fold change)
SQV IDV APV LPV ATV TPV
HIV104pre 0.0073 ± 0.0014 0.042 ± 0.003 0.029 ± 0.002 0.034 ± 0.002 0.002 ± 0.0004 0.16 ± 0.03
HIVA 0.075 ± 0.001 (10) 0.59 ± 0.04 (14) 0.074 ± 0.013 (3) 0.26 ± 0.014 (8) 0.024 ± 0.003 (12) 0.36 ± 0.007 (2)
HIVB 0.36 ± 0.001 (49) >1 (>24) >1 (>34) >1 (>29) 0.28 ± 0.01 (140) 0.18 ± 0.01 (1)
HIVC 0.032 ± 0.002 (4) >1 (>24) 0.37 ± 0.01 (11) >1 (>29) 0.034 ± 0.004 (17) 0.17 ± 0.04 (1)
HIVG 0.030 ± 0.001 (4) 0.36 ± 0.1 (9) 0.43 ± 0.04 (15) 0.26 ± 0.04 (8) 0.043 ± 0.022 (22) 0.24 ± 0.08 (2)
HIVTM 0.26 ± 0.04 (36) >1 (>24) 0.32 ± 0.007 (11) >1 (>29) 0.065 ± 0.008 (33) 0.38 ± 0.05 (2)
HIVMM 0.22 ± 0.01 (29) >1 (>24) 0.32 ± 0.03 (11) 0.59 ± 0.004 (17) 0.21 ± 0.02 (105) 0.35 ± 0.007 (2)
HIVSS 0.17 ± 0.004 (23) >1 (>24) 0.13 ± 0.01 (4) 0.21 ± 0.04 (6) 0.032 ± 0.006 (16) 0.41 ± 0.14 (3)
HIVJSL 0.30 ± 0.02 (41) >1 (>24) 0.78 ± 0.1 (27) >1 (>29) 0.43 ± 0.04 (215) 0.23 ± 0.05 (1)
HIVEV 0.36 ± 0.05 (49) 0.25 ± 0.02 (6) >1 (>34) >1 (>29) 0.43 ± 0.04 (215) 0.066 ± 0.016 (0.4)
HIVES 0.45 ± 0.01 (62) >1 (>24) >1 (>34) 0.41 ± 0.01 (12) 0.032 ± 0.004 (16) 0.34 ± 0.01 (2)
HIV13-52 0.029 ± 0.003 (4) 0.32 ± 0.03 (7) 0.030 ± 0.003 (1) 0.22 ± 0.1 (6) 0.021 ± 0.007 (11) 0.10 ± 0.01 (0.6)
a

IC50s were determined by using PHA-PBMCs as target cells, and the inhibition of p24 Gag protein production by each drug was used as the endpoint. Numbers in parentheses represent the n-fold change of the IC50 for each isolate compared to the IC50 for wild-type strain HIV104pre. All assays were conducted in duplicate or triplicate, and the data shown represent mean values ±1 standard deviation derived from the results of three independent experiments. PHA-PBMCs were derived from a single donor in each independent experiment.